In Section C, individuals will get ABBV-744 and oral navitoclax. In Section D, members will get ABBV-744 and ruxolitinib. Individuals will obtain treatment until condition progression or even the contributors are unable to tolerate the study drugs. Ubiquitin-associated proteins that control The steadiness of critical super enhancer-mediated proteins have also https://abbv-744-for-small-cell-l01346.liberty-blog.com/32161989/the-2-minute-rule-for-abbv-744-and-other-brd4-inhibitors-comparison